Secunderabad Chronicle

Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025

DelveInsight reports that the Non-Small Cell Lung Cancer (NSCLC) treatment pipeline includes over 10 prominent companies actively developing more than 10 therapeutic candidates for the disease.

Non-small Cell Lung Cancer Overview:

Non-small-cell lung cancer (NSCLC) encompasses all types of epithelial lung cancers excluding small-cell lung cancer (SCLC) and accounts for roughly 85% of all lung cancer cases. NSCLC is mainly classified into three types:

a) Adenocarcinoma – This type originates in the mucus-producing cells within the lung’s air sacs, usually in the outer regions of the lungs. It is the most common form of lung cancer in both smokers and nonsmokers, particularly in individuals under 45, and generally tends to grow more slowly than other lung cancers.

b) Squamous cell carcinoma – Arising in the cells lining the airways, this type makes up around 25% of lung cancers.

c) Large cell (undifferentiated) carcinoma – This form grows and spreads more aggressively, making it more difficult to treat, and accounts for about 10% of cases.

Treatment for non-small-cell adenocarcinoma depends largely on the stage of the disease, with surgery—often involving partial or complete removal of the lung—being a primary option if the cancer has not metastasized.

Request for a detailed insights report on Non-small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

“Non-small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report

• DelveInsight’s Non-small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Non-small Cell Lung Cancer treatment.

• In September 2025, AbbVie announced that it had submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of elotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) exhibiting c-Met protein overexpression.

• In August 2025, the FDA granted Fast Track designation to Deltacel (KB-GDT-01) in combination with low-dose radiation therapy for the potential treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after two or more prior lines of standard-of-care treatments, including immune checkpoint inhibitors, platinum-based chemotherapy, and targeted therapy.

• In July 2025, Nuvalent announced that the first patient had been dosed in the HEROEX-1 Phase Ia/Ib clinical trial of NVL-330, its novel HER2-selective inhibitor.

• Key Non-small Cell Lung Cancer companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc, and others are evaluating new drugs for Non-small Cell Lung Cancer to improve the treatment landscape.

• Promising Non-small Cell Lung Cancer pipeline therapies in various stages of development include AMG 510, CMP 001, and others.

Non-small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Non-small Cell Lung Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-small Cell Lung Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-small Cell Lung Cancer market.

Download our free sample page report on Non-small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-small Cell Lung Cancer Emerging Drugs

• AMG 510: Amgen

• CMP 001: Cytos Biotechnology

Non-small Cell Lung Cancer Companies

More than 10 leading companies are actively developing treatments for Non-Small-Cell Lung Cancer (NSCLC). Among them, Amgen has drug candidates currently in the mid to late stages of development, specifically in Phase I clinical trials.

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Non-small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Non-small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-small Cell Lung Cancer Therapies and Key Companies: Non-small Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-small Cell Lung Cancer Pipeline Therapeutic Assessment

• Non-small Cell Lung Cancer Assessment by Product Type

• Non-small Cell Lung Cancer By Stage

• Non-small Cell Lung Cancer Assessment by Route of Administration

• Non-small Cell Lung Cancer Assessment by Molecule Type

Download Non-small Cell Lung Cancer Sample report to know in detail about the Non-small Cell Lung Cancer treatment market @ Non-small Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction

2. Executive Summary

3. Non-small Cell Lung Cancer Current Treatment Patterns

4. Non-small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Non-small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-small Cell Lung Cancer Discontinued Products

13. Non-small Cell Lung Cancer Product Profiles

14. Non-small Cell Lung Cancer Key Companies

15. Non-small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Non-small Cell Lung Cancer Unmet Needs

18. Non-small Cell Lung Cancer Future Perspectives

19. Non-small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-small Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/